Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation

Alessandro Russo; Katherine A. Scilla; Ranee Mehra; Allison Gittens; Michael G. McCusker; Diego de Miguel-Perez; Jorge E. Gomez; Ariel Peleg; Marzia Del Re; Christian D. Rolfo

doi:10.1016/j.cllc.2023.07.003

Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation

Alessandro Russo
, Katherine A. Scilla
, Ranee Mehra
, Allison Gittens
, Michael G. McCusker
, Diego de Miguel-Perez
, Jorge E. Gomez
, Ariel Peleg
, Marzia Del Re
, Christian D. Rolfo

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

• Plasma NGS can track the clonal evolution of EGFR-mutated NSCLCs. • C797S mutation is one of the most common mechanisms of acquired resistance to osimertinib. • First generation can target C797S mutants, albeit responses are usually transient. • Novel therapeutic strategies are eagerly awaited for overcoming C797S mutation.

Original language	English
Pages (from-to)	660-665
Number of pages	6
Journal	Clinical Lung Cancer
Volume	24
Issue number	7
DOIs	https://doi.org/10.1016/j.cllc.2023.07.003
State	Published - Nov 2023

Keywords

Acquired resistance
Liquid biopsy
Osimertinib
Plasma NGS
Rechallenge

Access to Document

10.1016/j.cllc.2023.07.003

Cite this

@article{27086d62cc184c6c977e48af26edf59a,

title = "Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation",

abstract = "• Plasma NGS can track the clonal evolution of EGFR-mutated NSCLCs. • C797S mutation is one of the most common mechanisms of acquired resistance to osimertinib. • First generation can target C797S mutants, albeit responses are usually transient. • Novel therapeutic strategies are eagerly awaited for overcoming C797S mutation.",

keywords = "Acquired resistance, Liquid biopsy, Osimertinib, Plasma NGS, Rechallenge",

author = "Alessandro Russo and Scilla, \{Katherine A.\} and Ranee Mehra and Allison Gittens and McCusker, \{Michael G.\} and \{de Miguel-Perez\}, Diego and Gomez, \{Jorge E.\} and Ariel Peleg and \{Del Re\}, Marzia and Rolfo, \{Christian D.\}",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = nov,

doi = "10.1016/j.cllc.2023.07.003",

language = "English",

volume = "24",

pages = "660--665",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy

T2 - Management of C797S Acquired Mutation

AU - Russo, Alessandro

AU - Scilla, Katherine A.

AU - Mehra, Ranee

AU - Gittens, Allison

AU - McCusker, Michael G.

AU - de Miguel-Perez, Diego

AU - Gomez, Jorge E.

AU - Peleg, Ariel

AU - Del Re, Marzia

AU - Rolfo, Christian D.

PY - 2023/11

Y1 - 2023/11

N2 - • Plasma NGS can track the clonal evolution of EGFR-mutated NSCLCs. • C797S mutation is one of the most common mechanisms of acquired resistance to osimertinib. • First generation can target C797S mutants, albeit responses are usually transient. • Novel therapeutic strategies are eagerly awaited for overcoming C797S mutation.

AB - • Plasma NGS can track the clonal evolution of EGFR-mutated NSCLCs. • C797S mutation is one of the most common mechanisms of acquired resistance to osimertinib. • First generation can target C797S mutants, albeit responses are usually transient. • Novel therapeutic strategies are eagerly awaited for overcoming C797S mutation.

KW - Acquired resistance

KW - Liquid biopsy

KW - Osimertinib

KW - Plasma NGS

KW - Rechallenge

UR - https://www.scopus.com/pages/publications/85166186004

U2 - 10.1016/j.cllc.2023.07.003

DO - 10.1016/j.cllc.2023.07.003

M3 - Article

C2 - 37487787

AN - SCOPUS:85166186004

SN - 1525-7304

VL - 24

SP - 660

EP - 665

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 7

ER -

Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation

Abstract

Keywords

Access to Document

Fingerprint

Cite this